US20060257330A1 - Powdery pharmaceutical compositions for inhalation - Google Patents

Powdery pharmaceutical compositions for inhalation Download PDF

Info

Publication number
US20060257330A1
US20060257330A1 US11/492,105 US49210506A US2006257330A1 US 20060257330 A1 US20060257330 A1 US 20060257330A1 US 49210506 A US49210506 A US 49210506A US 2006257330 A1 US2006257330 A1 US 2006257330A1
Authority
US
United States
Prior art keywords
carrier
composition according
powder composition
magnesium stearate
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/492,105
Inventor
Rosella Musa
Paolo Ventura
Paolo Chiesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8167234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060257330(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to US11/492,105 priority Critical patent/US20060257330A1/en
Publication of US20060257330A1 publication Critical patent/US20060257330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/47—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers

Definitions

  • This invention relates to improved powdery pharmaceutical compositions for use in dry powder inhalers.
  • the improvement is concerned with mechanical stability, performances and safety.
  • Inhalation anti-asthmatics are widely used in the treatment of reversible airway obstruction, inflammation and hyperresponsiveness.
  • MDIs pressurised metered dose inhalers
  • DPIs Dry powder inhalers
  • DPIs can be divided into two basic types:
  • MDPIs are considered more convenient to the patient than single dose DPIs, not only because they provide a number of doses sufficient for. longer treatment cycles but also because of their ease of use and unobtrusiveness.
  • Dry powder dosage forms are generally formulated by mixing the cohesive micronised drug with coarse carrier particles, giving rise to ordered mixture where the micronised active particles adhere to the surface of the carrier particles whilst in the inhaler device.
  • the carrier material most commonly lactose, makes the micronised powder less cohesive and improves its flowability, making easier handling the powder during the manufacturing process (pouring, filling etc.).
  • the small drug particles separate from the surface of carrier particles and penetrates into the lower lungs, while the larger carrier particles are mostly deposited in the oropharyngeal cavity.
  • the redispersion of drug particles from the carrier surface is regarded as the most critical factor which governs the availability of the medicament to the lungs. This will depend on the mechanical stability of the powder mix and the way this is influenced by the adhesion characteristics between the drug and the carrier and the external forces required to break up the non covalent bonds formed between adhering particles. Too strong bonds between adhering particles may prevent indeed the separation of the micronised drug particles from the surface of carrier particles. ID particular, the efficiency of the redispersion process is strictly dependent on the carrier surface properties, the actual particle size of both the drug and the carrier and the drug to carrier ratio.
  • Fisons patents GB 1242211 and GB 1381872 described powders for inhalation obtained by simple mixing of a medicament with a particle size of less than 10 microns and a coarse carrier whose particle size falls in a well defined range. They also disclosed that it may be useful to coat the surfaces of the particles and/or carrier with pharmaceutically acceptable material, such as stearic acid or polymers for giving a sustained release action to the medicament.
  • Chiesi WO A 87 05213 described a carrier, comprising a conglomerate of a solid water-soluble carrier and a lubricant, preferably 1% magnesium stearate, for improving the technological properties of the powder in such a way as to remedy to the reproducibility problems encountered after the repeated use of the inhaler device.
  • the reported drawbacks can be solved by adding physiologically acceptable/water-soluble additives with anti-adherent properties which do not make segregation of the active particles from the surfaces of the carrier particles during manufacturing of the dry powder and in the delivery device before use.
  • the anti-adherent material preferably 1-2% leucine in particulate form, promote the release of the active particles by saturating the high energy sites of the carrier particles.
  • magnesium stearate being highly surface active, should be added in particularly small amounts', the use of such excipient is considered not advisable.
  • lubricants like magnesium stearate can be advantageously and safely used as excipient for powdery pharmaceutical composition in such amount by weight based on the total weight of the powder of less than 0.5%; for steroids, the optimum amount of additive turned out to be 0.25%, whereas, for salbutamol base, it turned out to be 0.10%. Contrary to the teaching of the prior art (Peart et al. Pharm. Res. 14, S 142, 1997), 0.1% of magnesium stearate is sufficient for increasing in a significant way the fine particle dose, when salbutamol base instead of sulphate is used.
  • the invention also provides a method for producing a homogeneous carrier for powders for inhalation independently on the scale of mixing, the method including a step for coating the most as possible surface of the carrier particles with a little amount of lubricant.
  • a step for coating the most as possible surface of the carrier particles with a little amount of lubricant we have indeed found that it is advantageous to attain the highest as possible degree of coating of the carrier particles surface with the lubricant to increase the release of the active particles and, hence, the ‘respirable’ fraction.
  • the film forming properties of lubricants depend on the mixing time and significantly affect the compressibility characteristics of powders for tablets, but an advantageous relationship between the degree of coating and the ‘respirable’ fraction has never been reported before.
  • this is another aspect of the invention that use of lubricants in such little amount for coating the carrier, is sufficient for improving the flowability of the powder without causing mechanical stability problems of the mixture before use.
  • magnesium stearate in such a small amount is safe and does not produce any toxicologically relevant effect after repeated administration.
  • the carrier of the invention is prepared by mixing the carrier particles and the lubricant particles for at least 2 min in a mixer in such a way as that no significant change in the particle size of the carrier particle occurs.
  • the carrier is mixed for at least 30 min using a rotating body mixer with a rotating speed between 5-100 r.p.m. or a stationary body mixer with a rotating mixing blade or a high-speed mixer. More preferably, the carrier is mixed for al least two hours in a Turbula mixer at 16 r.p.m.
  • the carrier particles and the lubricant particles are mixed until the degree of molecular surface coating is more than 10% as determined by water contact angle measurement.
  • carrier particles and lubricant particles made of magnesium stearate are mixed until the water contact angle of the ‘coated’ carrier particles is more than 36° corresponding to more than 10% degree of molecular surface coating; more preferably, the water contact angle should be more than 50° corresponding to more than 23% degree of molecular surface coating.
  • the carrier particles may be composed of any pharmacologically inert material or combinations of material acceptable for inhalation.
  • the carrier particles are composed on one or more crystalline sugars.
  • the carrier particles are particles of ⁇ -lactose monaohydrate.
  • all the carrier particles have a particle size in the range 20-1000 ⁇ m, more preferably in the range 90-150 ⁇ m.
  • the preferred lubricant is any type of magnesium stearate which may be crystalline or amorphous; its use is described in the embodiments of the invention by way of examples which do not limit it in any way.
  • lubricants such as stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol, sucrose monopalmitate and sodium benzoate, could turn out to be suitable depending on the type of carrier and drug used.
  • At least 50% by weight of the lubricant particles have a particle size more than 4 ⁇ m.
  • at least 60% of the lubricant particles made of magnesium stearate have a particle size more than 5 ⁇ m, with a specific surface area in the range 0.5-2.5 m 2 /g measured by Malvern.
  • the ratio between the carrier and the drug are mixed will depend on the type of inhaler device used and the required dose.
  • the at least 90% of the particles of the drug have a particle size less than 10 ⁇ m, preferably less than 6 ⁇ m.
  • Drugs include those products which are usually administered by inhalation for the treatment of respiratory diseases, i.e. ⁇ -agonists, like salbutamol, formoterol, salmeterol, terbutaline and their salts, steroids like beclometasone dipropionate, flunisolide, budesonide, others like ipratropium bromide.
  • ⁇ -agonists like salbutamol, formoterol, salmeterol, terbutaline and their salts
  • steroids like beclometasone dipropionate
  • flunisolide flunisolide
  • budesonide others like ipratropium bromide.
  • the invention also provides a powdery pharmaceutical composition for use in a dry powder inhaler, the powder including active particles and a carrier where the surface of the carrier particles carrying the active particles is partially coated with a film of lubricant.
  • Samples of the carrier were prepared by mixing of ⁇ -lactose monohydrate (Meggle D 30) fraction 90-150 ⁇ m with 0.1%, 0.25% or 0.5% magnesium stearate for several hours in a Turbula mixer. Powders mixtures with different BDP concentrations (100, 200 and 400 ⁇ g/dose) were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • Multidose devices (Pulvinal®) filled with the mixtures were then tested by using a twin-stage impinger (TSI), Apparatus A (BP 93, Appendix XVII C, A194).
  • the fine particle dose is calculated as a percentage of the total amount of drug delivered from the device (stage 1+stage 2), that reaches stage 2 of TSI.
  • the results are summarised in Tables 1, 2 and 3 (standard deviations S.D., given in parentheses).
  • Powder mixtures containing 200 ⁇ g/dose of micronised salbutamol base were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • a sample of the carrier was prepared by mixing of ⁇ -lactose monohydrate (Meggle D 30) fraction 90-150 ⁇ m with 0.25% magnesium stearate for two hours in Turbula-T100 mixer at 16 r.p.m.
  • Powder mixtures containing 100 ⁇ g/dose of micronised budesonide were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • Magnesium stearate significantly increases the fine particle dose of budesonide (t 8.8, p ⁇ 0.001); TABLE 5 Formulation Mg Shot Fine particle (100 stearate weight Stage 2 Delivered dose* ⁇ g/dose) (%) (mg) ( ⁇ g) dose ( ⁇ g) (Budesonide %) BUD 1 0 22.0 — 80.0 21.4 (4.7) BUD 2 0.25 21.5 — 79.3 33.6 (2.6) *Average values obtained from three inhalers by actuating 5 shots from each inhaler.
  • Powder mixtures containing 200 ⁇ g/dose of micronised BDP were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • Composition of BDP Pulvinal® (100, 200 and 400 ⁇ g/dose): Strength ( ⁇ g/dose) Ingredient (mg) 100 200 400 BDP 0.100 0.200 0.400 ⁇ -Lactose monohydrate 25.832 25.735 25.536 Magnesium stearate 0.067 0.064 0.064
  • Typical values in coefficient of variation (CV) of BDP samples drawn from, a mix judged to be satisfactory are ⁇ 5.0%. After the imposition of an enhanced gravitational stress, BDP samples show a CV which varies from 2.7% and 7.8%. Despite the intense vibration, these variations have not increased significantly and are consistent with good inhaler performance when judged in terms of dose uniformity. Samples taken from the top of the bed are very similar to the bottom samples.
  • a batch of BDP 400 ⁇ g/shot powder was prepared by mixing of the drug and the carrier (lactose/magnesium stearate 99.75/0.25% w/w) under the conditions reported in Example 1. Devices were filled with the mixture and the fine particle delivery of magnesium stearate was determined using a TSI apparatus. The results are reported in Table 12. TABLE 12 Total Mg Total Shot weight stearate Mg stearate Mg stearate stage 2 (mg) (%) ( ⁇ g) ( ⁇ g) Mean 26.4 0.259 68 19 S.D. 0.31 0.017 4.18 2.39 CV % 1.18 6.52 6.13 12.5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Powdery pharmaceutical compositions including an active ingredient and carrier particles containing only a small amount of lubricant, 0.05-0.5% by weight, are used to prepare dry powder inhalers in order to increase the fine particle dose. A process for coating the surface of the carrier particles with such little amount of lubricant is also provided. Use of limited amount of lubricant is safe and provides ordered stable mixtures without segregation of the active particles during handling and before use.

Description

  • This invention relates to improved powdery pharmaceutical compositions for use in dry powder inhalers. The improvement is concerned with mechanical stability, performances and safety.
  • Inhalation anti-asthmatics are widely used in the treatment of reversible airway obstruction, inflammation and hyperresponsiveness.
  • Presently, the most widely used systems for inhalation therapy are the pressurised metered dose inhalers (MDIs). which use a propellant to expel droplets containing the pharmaceutical product to the respiratory. tract.
  • However, despite their practicality and popularity, MDIs have some disadvantages:
    • i) the majority of the dose released deposits in the oropharynx by impaction and only a small percentage penetrates directly into the lower lungs;
    • ii) the already small proportion of drug which penetrates the bronchial tree may be further reduced by poor inhalation technique;
    • iii) last but not least, chlorofluorocarbons (CFCs), such as freons contained as propellants in MDIs, are disadvantageous on environmental grounds as they have a proven damaging effect on the atmosphenic ozone layer.
  • Dry powder inhalers (DPIs) constitute a valid alternative to MDIs for the administration of drugs to airways. The main advantages of DPIs are:
    • i) being breath-actuated delivery systems, they do not require co-ordination of actuation since release of the drug is dependent on the patient own inhalation;
    • ii) they do not contain propellants acting as environmental hazards;
    • iii) the quantity deposited by impaction in the oropharynx is lower.
  • DPIs can be divided into two basic types:
    • i) single dose inhalers, for the administration of single subdivided doses of the active compound;
    • ii) multidose dry powder inhalers (MDPIs), pre-loaded with quantities of active principles sufficient for longer treatment cycles.
  • MDPIs are considered more convenient to the patient than single dose DPIs, not only because they provide a number of doses sufficient for. longer treatment cycles but also because of their ease of use and unobtrusiveness.
  • Dry powder dosage forms are generally formulated by mixing the cohesive micronised drug with coarse carrier particles, giving rise to ordered mixture where the micronised active particles adhere to the surface of the carrier particles whilst in the inhaler device.
  • The carrier material, most commonly lactose, makes the micronised powder less cohesive and improves its flowability, making easier handling the powder during the manufacturing process (pouring, filling etc.). During inhalation, the small drug particles separate from the surface of carrier particles and penetrates into the lower lungs, while the larger carrier particles are mostly deposited in the oropharyngeal cavity.
  • The redispersion of drug particles from the carrier surface is regarded as the most critical factor which governs the availability of the medicament to the lungs. This will depend on the mechanical stability of the powder mix and the way this is influenced by the adhesion characteristics between the drug and the carrier and the external forces required to break up the non covalent bonds formed between adhering particles. Too strong bonds between adhering particles may prevent indeed the separation of the micronised drug particles from the surface of carrier particles. ID particular, the efficiency of the redispersion process is strictly dependent on the carrier surface properties, the actual particle size of both the drug and the carrier and the drug to carrier ratio. Consequently, different approaches aimed at modulating one or more of these parameters have been proposed to promote the release of the drug particles from the carrier particles and, hence, to increase the percentage of the respirable fraction. In the prior art, the use of a ternary component, with lubricant or anti-adherent properties, has been also suggested as a solution of the technical problem.
  • Fisons patents GB 1242211 and GB 1381872 described powders for inhalation obtained by simple mixing of a medicament with a particle size of less than 10 microns and a coarse carrier whose particle size falls in a well defined range. They also disclosed that it may be useful to coat the surfaces of the particles and/or carrier with pharmaceutically acceptable material, such as stearic acid or polymers for giving a sustained release action to the medicament.
  • Chiesi WO A 87 05213 described a carrier, comprising a conglomerate of a solid water-soluble carrier and a lubricant, preferably 1% magnesium stearate, for improving the technological properties of the powder in such a way as to remedy to the reproducibility problems encountered after the repeated use of the inhaler device.
  • Staniforth et al. (J. Pharm. Pharmacol. 34, 141-145, 1982) observed that magnesium stearate is able to modify the adhesion of salicylic acid to sucrose but, the amount used (0.5-4.0%) destabilises the mixture to the extent that significant segregation occurs.
  • Kassem (London University Thesis, 1990) studied the effect of 1.5% w/w magnesium stearate or Aerosil 200 (trade name for colloidal silicon dioxide) on the de-aggregation of powders made of salbutamol sulphate and lactose. Although the ‘respirable’ fraction increased when magnesium stearate was added, the reported amount is too great and reduces the mechanical stability of the mixture before use. Furthermore, being magnesium stearate poorly water-soluble, its presence in such amount may rise some concerns as to a potential irritation or toxicity of this excipient, part of which can be inhaled by the patient together with the active ingredient. According to Staniforth (WO 96/23485), the reported drawbacks can be solved by adding physiologically acceptable/water-soluble additives with anti-adherent properties which do not make segregation of the active particles from the surfaces of the carrier particles during manufacturing of the dry powder and in the delivery device before use. In the said document, the anti-adherent material, preferably 1-2% leucine in particulate form, promote the release of the active particles by saturating the high energy sites of the carrier particles. Although it is generically disclosed that magnesium stearate, being highly surface active, should be added in particularly small amounts', the use of such excipient is considered not advisable.
  • It has now been discovered, and this is an object of the present invention, that lubricants like magnesium stearate can be advantageously and safely used as excipient for powdery pharmaceutical composition in such amount by weight based on the total weight of the powder of less than 0.5%; for steroids, the optimum amount of additive turned out to be 0.25%, whereas, for salbutamol base, it turned out to be 0.10%. Contrary to the teaching of the prior art (Peart et al. Pharm. Res. 14, S 142, 1997), 0.1% of magnesium stearate is sufficient for increasing in a significant way the fine particle dose, when salbutamol base instead of sulphate is used.
  • The invention also provides a method for producing a homogeneous carrier for powders for inhalation independently on the scale of mixing, the method including a step for coating the most as possible surface of the carrier particles with a little amount of lubricant. We have indeed found that it is advantageous to attain the highest as possible degree of coating of the carrier particles surface with the lubricant to increase the release of the active particles and, hence, the ‘respirable’ fraction. In the prior art, it was already known that the film forming properties of lubricants depend on the mixing time and significantly affect the compressibility characteristics of powders for tablets, but an advantageous relationship between the degree of coating and the ‘respirable’ fraction has never been reported before. We have also found, and this is another aspect of the invention, that use of lubricants in such little amount for coating the carrier, is sufficient for improving the flowability of the powder without causing mechanical stability problems of the mixture before use.
  • Finally we have found that the introduction of magnesium stearate in such a small amount is safe and does not produce any toxicologically relevant effect after repeated administration.
  • Advantageously the carrier of the invention is prepared by mixing the carrier particles and the lubricant particles for at least 2 min in a mixer in such a way as that no significant change in the particle size of the carrier particle occurs. Preferably, the carrier is mixed for at least 30 min using a rotating body mixer with a rotating speed between 5-100 r.p.m. or a stationary body mixer with a rotating mixing blade or a high-speed mixer. More preferably, the carrier is mixed for al least two hours in a Turbula mixer at 16 r.p.m.
  • Advantageously, the carrier particles and the lubricant particles are mixed until the degree of molecular surface coating is more than 10% as determined by water contact angle measurement. Preferably, carrier particles and lubricant particles made of magnesium stearate are mixed until the water contact angle of the ‘coated’ carrier particles is more than 36° corresponding to more than 10% degree of molecular surface coating; more preferably, the water contact angle should be more than 50° corresponding to more than 23% degree of molecular surface coating.
  • The carrier particles may be composed of any pharmacologically inert material or combinations of material acceptable for inhalation. Advantageously, the carrier particles are composed on one or more crystalline sugars. Preferably, the carrier particles are particles of α-lactose monaohydrate.
  • Advantageously, all the carrier particles have a particle size in the range 20-1000 μm, more preferably in the range 90-150 μm.
  • The preferred lubricant is any type of magnesium stearate which may be crystalline or amorphous; its use is described in the embodiments of the invention by way of examples which do not limit it in any way.
  • Other lubricants, such as stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol, sucrose monopalmitate and sodium benzoate, could turn out to be suitable depending on the type of carrier and drug used.
  • Advantageously, at least 50% by weight of the lubricant particles have a particle size more than 4 μm. Preferably, at least 60% of the lubricant particles made of magnesium stearate have a particle size more than 5 μm, with a specific surface area in the range 0.5-2.5 m2/g measured by Malvern.
  • The ratio between the carrier and the drug are mixed will depend on the type of inhaler device used and the required dose.
  • Advantageously, the at least 90% of the particles of the drug have a particle size less than 10 μm, preferably less than 6 μm.
  • Drugs include those products which are usually administered by inhalation for the treatment of respiratory diseases, i.e. β-agonists, like salbutamol, formoterol, salmeterol, terbutaline and their salts, steroids like beclometasone dipropionate, flunisolide, budesonide, others like ipratropium bromide.
  • In a general aspect, the invention also provides a powdery pharmaceutical composition for use in a dry powder inhaler, the powder including active particles and a carrier where the surface of the carrier particles carrying the active particles is partially coated with a film of lubricant.
    • EXAMPLE 1
  • Determination of the Suitable Amount of Magnesium Stearate to be Added in beclomethasone-17,21-dipropionate (BDP) Powders for Inhalation
  • Samples of the carrier were prepared by mixing of α-lactose monohydrate (Meggle D 30) fraction 90-150 μm with 0.1%, 0.25% or 0.5% magnesium stearate for several hours in a Turbula mixer. Powders mixtures with different BDP concentrations (100, 200 and 400 μg/dose) were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • Multidose devices (Pulvinal®) filled with the mixtures were then tested by using a twin-stage impinger (TSI), Apparatus A (BP 93, Appendix XVII C, A194). The fine particle dose is calculated as a percentage of the total amount of drug delivered from the device (stage 1+stage 2), that reaches stage 2 of TSI. The results are summarised in Tables 1, 2 and 3 (standard deviations S.D., given in parentheses).
  • No significant increase in fine particle dose is obtained from increasing the concentration of magnesium stearate above 0.25%.
    TABLE 1
    Formulation Mg Shot Fine particle
    (100 stearate weight Stage 2 Delivered dose*
    μg/dose) (%) (mg) (μg) dose (μg) (BDP %)
    BDP 1 0.10 26.7 (0.3) 22.5 (3.5) 99.7 (0.6) 21.9 (2.8)
    BDP 2 0.25 26.8 (0.1) 33.0 (5.6) 95.3 (0.6) 34.5 (6.2)
  • TABLE 2
    Fine
    Formulation Mg Shot particle
    (200 stearate weight Stage 2 Delivered dose*
    μg/dose) (%) (mg) (μg) dose (μg) (BDP %)
    BDP 1 0 24.8 (0.4) 14.2 (5.7)  192 (14.0)  7.3 (2.6)
    BDP 2 0.10 26.6 (0.4) 20.3 (4.6) 215 (2.3)  9.5 (2.2)
    BDP 3 0.25 26.8 (0.6) 48.0 (8.5) 192 (7.8) 25.0 (3.7)
    BDP 4 0.50 26.7 (0.2) 32.3 (2.3) 193 (4.6) 16.7 (1.0)
  • TABLE 3
    Formulation Mg Shot Fine particle
    (400 stearate weight Stage 2 Delivered dose*
    μg/dose) (%) (mg) (μg) dose (μg) (BDP %)
    BDP 1 0 — — 355 (22.8)  7.3 (0.4)
    BDP 2 0.10 25.4 (0.3) 100 (11.0) 351 (4.5)  28.7 (3.4)
    BDP 3 0.25 25.1 (0.4) 142 (22.1) 375 (9.3)  37.9 (5.7)
    BDP 4 0.50 25.5 (0.3)  98 (44.7) 421 (18.4)  23.2 (10.3)
    • EXAMPLE 2
  • Determination of the Suitable Amount of Magnesium Stearate to be Added in Salbutamol Base Powders for Inhalation
  • Samples of the carrier were prepared as reported in Example 1.
  • Powder mixtures containing 200 μg/dose of micronised salbutamol base were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • The powder mixtures were filled into inhalers and tested as reported in Example 1.
  • The results are summarised in Table 4.
  • 0.1% Magnesium stearate is sufficient for increasing in a significant way (t=10.47, p<0.001) the fine particle dose, when salbutamol base instead of sulphate is used; no increase is obtained from increasing the concentration of magnesium stearate above this percentage.
    TABLE 4
    Fine particle
    Formulation Mg Shot dose*
    (200 stearate weight Stage 2 Delivered (Salbutamol
    μg/dose) (%) (mg) (μg) dose (μg) %)
    SALB 1 0 22.4 (0.4) 62.7 (5.3) 185 (5.1) 33.6 (2.9)
    SALB 2 0.1 26.8 (0.5) 71.3 (3.1) 171 (5.0) 41.8 (0.9)
    SALB 3 0.25 26.9 (0.2) 71.7 (6.1) 171 (1.7) 41.6.(3.2)
    SALB 4 0.5 26.5 (0.5) 68.7 (6.4) 172 (6.0) 39.9 (3.5)
    • EXAMPLE 3
  • Determination of the Suitable Amount of Magnesium Stearate to be Added in Budesonide Powders for Inhalation
  • A sample of the carrier was prepared by mixing of α-lactose monohydrate (Meggle D 30) fraction 90-150 μm with 0.25% magnesium stearate for two hours in Turbula-T100 mixer at 16 r.p.m.
  • Powder mixtures containing 100 μg/dose of micronised budesonide were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • The powder mixtures were filled into inhalers and tested as reported in Example 1.
  • The results are summarised in Table 5.
  • 0.25% Magnesium stearate significantly increases the fine particle dose of budesonide (t=8.8, p<0.001);
    TABLE 5
    Formulation Mg Shot Fine particle
    (100 stearate weight Stage 2 Delivered dose*
    μg/dose) (%) (mg) (μg) dose (μg) (Budesonide %)
    BUD 1 0 22.0 — 80.0 21.4 (4.7)
    BUD 2 0.25 21.5 — 79.3 33.6 (2.6)

    *Average values obtained from three inhalers by actuating 5 shots from each inhaler.
    • EXAMPLE 4
  • Preparation of the Carrier—Study of the Mixing Conditions
  • 40.528 kg (99.75% w/w) of α-Lactose monohydrate fraction 90-150 μm and 0.102 kg (0.25% w/w) of magnesium stearate were mixed in a Turbula mixer T 100 at 16 r.p.m. for several hours. At different mixing times samples were withdrawn and tested for uniformity of distribution of magnesium stearate, particle size, water contact angle and degree of molecular surface coating calculated according to Cassie et al. (Transactions of the Faraday Society 40; 546, 1944). To validate the process, three batches (40 kg) of the carrier were prepared.
  • The results are reported in Tables 6 and 7, respectively.
  • A uniform distribution of magnesium stearate was already achieved at 60 minutes blending time (mean value, {overscore (x)}, and coefficient of variation, CV %, are given); no significant change in the particle size was observed after both Malvern light-scattering and Alpine sieving analyses. By increasing the mixing time, an increase of the degree of coating occurs.
  • The three different batches give comparable results.
    TABLE 6
    Particle size Particle size Mg stearate Water contact Degree of
    Time Alpine Malvern uniformity angle coating
    min % <80μ % <90μ % <80μ % 90μ x % CV % degree %
    10′ — — — — — — 34 15
    20′ — — — — — — 36 17
    30′ 1.5 4.8 0.9 2.7 0.228 6.8 36 17
    60′ 0.3 2.8 0.9 2.6 0.235 6.1 36 17
    90′ 0.6 3.8 1.0 2.9 0.244 3.7 37 18
    120′ 0.7 3.4 0.9 2.7 0.239 7.2 39 20
    180′ 0.8 4.2 0.8 2.6 0.246 2.9 46 29
    240′ 1.4 6.3 0.8 2.6 — — 48 32
    300′ 0.7 6.6 0.9 2.6 — — 50 34
    360′ 0.7 7.0 1.0 2.8 — — 51 36
    420′ 0.9 7.0 0.9 2.8 — — 51 36
    480′ 0.8 7.5 0.8 2.6 — — 51 36

    α-Lactose monohydrate water contact angle 12°

    Magnesium stearate water contact angle 118°
  • TABLE 7
    Magnesium
    Particle size Particle size stearate Water
    Distribution distribution content contact
    Mixing (Alpine) (Malvern) uniformity angle
    Time % <80 μm % <90 μm % <80 μm % <90 μm x (%) CV (%) (degree)
    CARRIER 1
    10 min 34
    20 min 37
    30 min 1.5 4.8 0.9 2.7 0.228 6.8 36
    60 min 0.3 2.8 0.9 2.6 0.235 6.1 36
    90 min 0.6 3.8 1.0 2.9 0.244 3.7 37
    120 min  0.7 3.4 0.9 2.7 0.239 7.2 39
    CARRIER 2
    10 min 32
    20 min 36
    30 min 38
    60 min 0.9 7.2 1.0 3.1 0.196 9.6 38
    90 min 40
    120 min  1.5 8.1 1.1 3.3 0.231 10.4 42
    CARRIER 3
    10 min 32
    20 min 31
    30 min 33
    60 min 0.8 6.9 2.0 4.5 0.237 7.3 38
    90 min 42
    120 min  0.8 7.3 1.8 4.2 0.229 3.8 42
    • EXAMPLE 6
  • Relationship Between Different Mixing Time of the Carrier and Delivered Fine Particle Dose
  • 40.528 kg (99.75% w/w) of a-Lactose monohydrate fraction 90-150. μm and 0.102 kg (0.25% w/w) of magnesium stearate were mixed for several hours in Turbula T100 mixer at 16 r.p.m. At different mixing times, 2 kg samples were withdrawn and micronised BDP was added to each sample so that the nominal weight delivered by Pulvinale inhaler contained 200 μg BDP. The powder mixtures were filled into inhalers and tested as reported in Example 1.
  • The results are reported in Table 8.
  • By increasing the mixing time, a significant increase at 420 min of the fine particle dose occurs (t=5.2, p<0.001).
    TABLE 8
    Formulation
    (BDP 200 μg/dose)
    BDP 1 BDP 2 BDP 3
    Mixing time (min) 60 120 420
    Shot weight (mg) 27.8 (0.6) 28.1 (0.7) 28.2 (0.5)
    Fine particle dose* (%) 34.1 (8.1) 37.4 (4.7) 49.5 (7.8)
    Stage 2 (μg)  63.1 (12.0) 63.5 (8.1) 102.6 (17.1)
    Delivered dose (μg) 188.4 (21.1) 169.7 (7.1)  207.2 (9.0) 

    *Average values obtained from three inhalers by actuating 5 shots from each inhaler
    • EXAMPLE 7
  • Preparation of the Carrier—Comoarison Between Different Mixers
  • 40.528 kg (99.75% w/w) of α-Lactose monohydrate fraction 90-150 μm and 0.102 kg (0.25 % w/w) of magnesium stearate were mixed in a sigma-blade mixer for 30 min (water contact angle of 53° corresponding to 26% of molecularcoating)
  • Powder mixtures containing 200 μg/dose of micronised BDP were prepared by mixing of the carrier and the active ingredient for 30 min in a Turbula mixer at 32 r.p.m.
  • The powder mixtures were filled into inhalers and tested as reported in Example 1.
  • The results are surniarised in Table 9.
  • No significant difference was observed in the fine particle dose with respect to the powder obtained with the carrier prepared by using a Turbula mixer at 16 r.p.m. for 2 hours.
    TABLE 9
    Fine particle
    Formulation Shot Stage 2 Delivered dose
    (200 μg/dose) weight (mg) (μg) dose (μg) (BDP %)
    Turbula mixer 25.7 (2.8) 96.2 (7.6) 167.5 (5.7) 57.4 (4.3)
    Sigma-blade 26.6 (2.3) 106.2 (11.2) 192.1 (7.0) 55.2 (6.0)
    mixer
    • EXAMPLE 8
  • Segregation Tendency of BDP Bulk Powder Formulation Containing 0.25% Magnesium Stearate
  • Composition of BDP Pulvinal® (100, 200 and 400 μg/dose):
    Strength (μg/dose)
    Ingredient (mg) 100 200 400
    BDP 0.100 0.200 0.400
    α-Lactose monohydrate 25.832 25.735 25.536
    Magnesium stearate 0.067 0.064 0.064
  • The tendency of the powder to segregate was assessed according to Staniforth et al. J. (Pharm. Pharmacol. 34, 700-706, 1982).
  • Approximately 15 g of powder was filled into a small plastic cylinder, 80 mm long and 12 mm in diameter, closed at one end and which could be split along its axis. This allowed the characterisation of both BDP and magnesium stearate on the same level in the same bulk mixture. The tube was mounted in a vibrator (Derrinton VP4) and vibrated at 50 Hz at a force of 2 g for ten minutes. The tube was then placed in a horizontal position, divided and 15 samples, each of about 50 mg accurately weighed, taken from along its length. The samples were analysed for BDP by HPLC and for magnesium stearate by atomic absorption. The experiments were carried out in duplicate. The results are reported in Tables 10 and 11.
  • Typical values in coefficient of variation (CV) of BDP samples drawn from, a mix judged to be satisfactory are ≦5.0%. After the imposition of an enhanced gravitational stress, BDP samples show a CV which varies from 2.7% and 7.8%. Despite the intense vibration, these variations have not increased significantly and are consistent with good inhaler performance when judged in terms of dose uniformity. Samples taken from the top of the bed are very similar to the bottom samples.
  • In the case of magnesium stearate, variability between samples was somewhat greater than for BDP due to its lower concentration. However, no consistent change in the uniformity of distribution occurred after vibration and, as with BDP, the content of samples drawn from the top of the bed were not different to those drawn from the bottom. It can be concluded that the ordered mix is very stable and no segregation of BDP and magnesium stearate occurs.
    TABLE 10
    DRUG ASSAY (μg/mg)
    BDP BDP BDP
    400 μg/dose 200 μg/dose 100 μg/dose
    SAMPLE 1 2 1 2 1 2
    Top of
    Cylinder
    1 17.9 17.3 8.6 8.5 4.4 4.4
    2 20.5 17.1 7.5 7.6 3.5 3.5
    3 16.9 17.6 7.7 7.7 3.7 3.9
    4 18.0 16.9 7.7 7.8 3.8 3.9
    5 17.0 17.0 7.5 9.0 4.1 4.2
    6 17.2 17.1 7.6 7.8 3.9 3.8
    7 17.4 17.6 7.4 8.1 3.7 3.8
    8 17.2 17.1 7.6 7.7 4.2 3.8
    9 16.8 17.3 7.7 7.6 4.5 3.9
    10  16.9 16.5 8.3 8.0 3.6 3.8
    11  16.9 18.9 7.8 8.0 4.4 4.0
    12  21.1 18.1 7.9 7.9 3.9 3.9
    13  17.3 17.5 7.8 7.3 3.9 4.2
    14  19.4 17.1 7.7 7.7 4.2 4.1
    15  18.0 19.1 7.8 8.0 4.4 3.9
    Bottom of
    Cylinder
    Mean 17.9 17.5 7.8 7.9 4.0 3.9
    SD 1.4 0.8 0.2 0.4 0.3 0.2
    CV(%) 7.6 4.3 2.7 5.0 7.8 4.7
  • TABLE 11
    MAGNESIUM ASSAY (μg/mg)
    BDP 400 μg/dose BDP 200 μg/dose BDP 100 μg/dose
    SAMPLE 1 2 UN-VIBRATED 1 2 UN-VIBRATED 1 2 UN-VIBRATED
    Top of
    cylinder
    1 0.115 0.124 0.101 0.101 0.092 0.125 0.082 0.076 0.103
    2 0.116 0.122 0.103 0.105 0.091 0.121 0.105 0.073 0.150
    3 0.114 0.123 0.107 0.108 0.093 0.125 0.096 0.091 0.104
    4 0.113 0.119 0.109 0.100 0.093 0.118 0.107 0.085 0.101
    5 0.114 0.126 0.110 0.115 0.089 0.135 0.094 0.083 0.110
    6 0.108 0.108 0.107 0.103 0.100 0.208 0.098 0.080 0.109
    7 0.111 0.113 0.110 0.111 0.096 0.107 0.104 0.114 0.109
    8 0.118 0.108 0.108 0.107 0.096 0.101 0.102 0.076 0.102
    9 0.107 0.104 0.106 0.106 0.094 0.102 0.099 0.082 0.103
    10  0.113 0.119 0.107 0.094 0.097 0.101 0.104 0.081 0.109
    11  0.114 0.120 0.109 0.091 0.094 0.096 0.090 0.086 0.105
    12  0.116 0.117 0.105 0.083 0.093 0.098 0.100 0.084 0.107
    13  0.112 0.101 0.103 0.114 0.077 0.100 0.092 0.079 0.104
    14  0.115 0.104 0.107 0.081 0.095 0.097 0.091 0.072 0.107
    15  0.106 0.097 0.102 0.080 0.076 0.100 0.086 0.085 0.105
    Bottom of
    Cylinder
    Mean 0.113 0.114 0.106 0.100 0.092 0.116 0.097 0.083 0.109
    SD 0.003 0.009 0.003 0.012 0.007 0.028 0.007 0.010 0.012
    (CV %) 3.1 8.2 2.7 11.6 7.3 24.6 7.6 12.0 10.9
    • EXAMPLE 9
  • Fine Particle Delivery of Magnesium Stearate
  • A batch of BDP 400 μg/shot powder was prepared by mixing of the drug and the carrier (lactose/magnesium stearate 99.75/0.25% w/w) under the conditions reported in Example 1. Devices were filled with the mixture and the fine particle delivery of magnesium stearate was determined using a TSI apparatus. The results are reported in Table 12.
    TABLE 12
    Total Mg Total
    Shot weight stearate Mg stearate Mg stearate stage 2
    (mg) (%) (μg) (μg)
    Mean 26.4 0.259 68 19
    S.D. 0.31 0.017 4.18 2.39
    CV % 1.18 6.52 6.13 12.5
  • Considering the low concentration of magnesium stearate in the formulation and the quantity found in stage 2 of TSI, the amount to be respirable will be very low.
  • This amount has been demonstrated to be safe after toxicity studies in dog.
  • Furthermore, acute and long term tolerance trials were carried out to evaluate toxicity of magnesium stearate in humans.
  • In the former, 18 healthy volunteers, included in a double blind randomised controlled cross-over design study, received a single dose containing 25.72 mg of lactose and 0.065 mg of magnesium stearate via Pulvinal® inhaler. The introduction of 0.25% magnesium stearate in powdery pharmaceutical formulation resulted to be safe.
  • In the long term randomised, controlled, parallel group study, the safety of magnesium stearate as a carrier was compared to that of lactose. 28 Mild asthmatic patients were treated for 3 months with 400 μg BDP b.i.d. delivered either with Pulvinal®, containing 0.065 mg of magnesium stearate per dose, or another commercially available DPI, containing 25.536 mg of lactose per dose. Bronchial biopsies and broncho-alveolar lavages performed at the beginning and at the end of trial did not evidence accumulation of magnesium in bronchi or in alveolar cells either in Pulvinal® or control group.

Claims (16)

1-26. (canceled)
27. A powder composition comprising active ingredient particles and carrier particles, the carrier comprising one or more crystalline sugars coated with a lubricant wherein said lubricant comprises magnesium stearate in an amount between 0.1 and 0.5 percent by weight of the composition.
28. A powder according to claim 27 wherein the crystalline sugar is made of α-lactose monohydrate.
29. A powder composition according to claim 27 wherein the carrier particles have a size within the range 90 and 150 μm.
30. A powder composition according to claim 27 wherein the active ingredient particles have a particle size less than 6 μm.
31. A powder composition according to claim 27 wherein the active ingredient particles include a steroid.
32. A powder composition according to claim 31 wherein the steroid is selected from the group consisting of beclometasone dipropionate, budesonide and its epimers and flunisolide.
33. A powder composition according to claim 27 wherein the active ingredient includes a β2-agonist.
34. A powder composition according to claim 33, wherein the β2-agonist is selected from the group consisting of salbutamol base, formoterol, salmeterol, terbutaline and the salts thereof.
35. A powder composition according to claim 27 wherein the carrier particles have a size within the range 20 and 1000 μm.
36. A powder composition according to claim 27 wherein the carrier consists of said one or more crystalline sugars coated with said lubricant.
37. A powder composition according to claim 27 wherein said lubricant consists of said magnesium stearate.
38. A powder composition according to claim 36 wherein said lubricant consists of said magnesium stearate.
39. A dry powder inhaler containing the powder composition according to claim 27 therein.
40. A method of treating the lungs in a patient in need thereof comprising administering an effective amount of the powder composition according to claim 27 to said patient.
41. The method according to claim 40, wherein the patient is treated for asthma.
US11/492,105 1999-03-05 2006-07-25 Powdery pharmaceutical compositions for inhalation Abandoned US20060257330A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/492,105 US20060257330A1 (en) 1999-03-05 2006-07-25 Powdery pharmaceutical compositions for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP1999/001449 WO2000053157A1 (en) 1999-03-05 1999-03-05 Improved powdery pharmaceutical compositions for inhalation
US09/603,620 US6528096B1 (en) 1999-03-05 2000-06-26 Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation
US10/358,174 US20030133880A1 (en) 1999-03-05 2003-02-05 Powdery pharmaceutical compositions for inhalation
US11/492,105 US20060257330A1 (en) 1999-03-05 2006-07-25 Powdery pharmaceutical compositions for inhalation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/358,174 Continuation US20030133880A1 (en) 1999-03-05 2003-02-05 Powdery pharmaceutical compositions for inhalation

Publications (1)

Publication Number Publication Date
US20060257330A1 true US20060257330A1 (en) 2006-11-16

Family

ID=8167234

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/603,620 Expired - Lifetime US6528096B1 (en) 1999-03-05 2000-06-26 Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation
US10/358,174 Abandoned US20030133880A1 (en) 1999-03-05 2003-02-05 Powdery pharmaceutical compositions for inhalation
US11/492,105 Abandoned US20060257330A1 (en) 1999-03-05 2006-07-25 Powdery pharmaceutical compositions for inhalation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/603,620 Expired - Lifetime US6528096B1 (en) 1999-03-05 2000-06-26 Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation
US10/358,174 Abandoned US20030133880A1 (en) 1999-03-05 2003-02-05 Powdery pharmaceutical compositions for inhalation

Country Status (17)

Country Link
US (3) US6528096B1 (en)
EP (1) EP1158958B1 (en)
AT (1) ATE363892T1 (en)
AU (1) AU3409399A (en)
BR (1) BR9917246A (en)
CY (1) CY1106817T1 (en)
CZ (1) CZ298489B6 (en)
DE (1) DE69936268T2 (en)
DK (1) DK1158958T3 (en)
ES (1) ES2286881T3 (en)
HU (1) HUP0200185A3 (en)
PL (1) PL196951B1 (en)
PT (1) PT1158958E (en)
SI (1) SI1158958T1 (en)
SK (1) SK286981B6 (en)
TR (1) TR200102567T2 (en)
WO (1) WO2000053157A1 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CA2347856C (en) 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
IT1309592B1 (en) * 1999-03-05 2002-01-24 Chiesi Farma Spa VEHICLE PARTICLES MODIFIED FOR USE IN THE PREPARATION OF PHARMACEUTICAL FORMULATIONS IN THE FORM OF POLYMERS FOR INHALATION AND
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ITMI991582A1 (en) 1999-07-16 2001-01-16 Chiesi Farma Spa DUST CONSTITUTED FROM PARTICLES HAVING THE PERFECTLY SMOOTH SURFACE FOR USE AS VEHICLES FOR THE PREPARATION OF INALA MIXTURES
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
PE20011227A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
IT1318514B1 (en) * 2000-05-12 2003-08-27 Chiesi Farma Spa FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
BR0015884A (en) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulations of stable pharmaceutical solutions for pressurized metered dose inhalers
ATE446085T1 (en) 2000-11-30 2009-11-15 Vectura Ltd PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION
AU2002222118A1 (en) † 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
JP2005507881A (en) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド Dry powder pharmaceutical formulation
DE60318938T2 (en) 2002-03-20 2009-01-22 Mannkind Corp., Valencia INHALER
JP2005530725A (en) * 2002-04-12 2005-10-13 カンピナ・ネーデルラント・ホールディング・ベスローテン・フェンノートシャップ Excipients used in dry powder inhalation formulations
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
US8273331B2 (en) 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP2006516531A (en) * 2002-08-21 2006-07-06 ノートン　ヘルスケアー　リミテッド Inhalation composition
CN102688224A (en) * 2003-04-14 2012-09-26 维克特拉有限公司 Device and pharmaceutical composition enhancing administration efficiency
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
CA2578175C (en) 2004-08-23 2014-10-14 Mannkind Corporation Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2007001094A1 (en) * 2005-06-29 2007-01-04 Sannamu Lee Artificial lung surfactant composition
EP1910394A4 (en) * 2005-07-29 2010-10-27 Rhode Island Education Modified oligonucleotides containing diphosphodiester internucleotide linkages
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
BRPI0707991B8 (en) 2006-02-22 2021-05-25 Mannkind Corp methods of preparing a dry powder medicine with an improved pharmaceutical property, said dry powder and using an effective amount of the dry powder
DK2046787T3 (en) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo [3,4-B] pyridine compounds, and their use as PDE4 inhibitors
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
DE102008014237A1 (en) * 2008-03-14 2009-09-17 J. Rettenmaier & Söhne Gmbh + Co. Kg Directly compressible tableting aid
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2570147B1 (en) 2008-06-13 2017-10-18 MannKind Corporation A dry powder inhaler and system for drug delivery
US9364619B2 (en) * 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (en) 2008-08-11 2018-02-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP3578169B1 (en) 2009-02-26 2024-06-26 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
LT2435025T (en) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20180079458A (en) 2009-06-12 2018-07-10 맨카인드 코포레이션 Diketopiperazine microparticles with defined specific surface areas
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
KR101730684B1 (en) 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. Process for preparing carrier particles for dry powders for inhalation
RU2531455C2 (en) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Systems and methods for dry powder drugs delivery
BR112012032330A2 (en) 2010-06-22 2016-11-08 Chiesi Farma Spa Inhalable dry powder formulation, use of a dry powder formulation, dry powder inhaler and packaging
KR101805958B1 (en) 2010-08-03 2017-12-07 키에시 파르마슈티시 엣스. 피. 에이. Dry powder formulation comprising a phophodiesterase inhibitor
WO2012041717A1 (en) * 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
EP2809780B1 (en) 2012-02-01 2018-05-02 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
KR20140147891A (en) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Aggregate particles
CN108057154B (en) 2012-07-12 2021-04-16 曼金德公司 Dry powder drug delivery system and method
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
JP6454323B2 (en) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド Method and system for conditioning particulate crystalline materials
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TR201407010A2 (en) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formulations.
CN105412049B (en) * 2014-09-16 2020-01-07 四川海思科制药有限公司 Medicinal composition for dry powder inhalant and preparation method thereof
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
SI3947384T1 (en) 2019-04-04 2024-03-29 Chiesi Farmaceutici S.P.A. Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2021013329A (en) 2019-04-29 2022-03-17 Insmed Inc Dry powder compositions of treprostinil prodrugs and methods of use thereof.
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2024133905A1 (en) 2022-12-22 2024-06-27 Stada Arzneimittel Ag Pharmaceutical composition for treating copd

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045828A (en) * 1994-12-22 2000-04-04 Astra Aktiebolag Powders for inhalation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
IT1204826B (en) * 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
IT1309592B1 (en) * 1999-03-05 2002-01-24 Chiesi Farma Spa VEHICLE PARTICLES MODIFIED FOR USE IN THE PREPARATION OF PHARMACEUTICAL FORMULATIONS IN THE FORM OF POLYMERS FOR INHALATION AND
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
US20040202516A1 (en) * 2003-04-11 2004-10-14 Lanser Jerry L. Attitude independent portable press for hand held tool and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045828A (en) * 1994-12-22 2000-04-04 Astra Aktiebolag Powders for inhalation

Also Published As

Publication number Publication date
SI1158958T1 (en) 2007-10-31
WO2000053157A1 (en) 2000-09-14
EP1158958A1 (en) 2001-12-05
EP1158958B1 (en) 2007-06-06
ES2286881T3 (en) 2007-12-01
SK286981B6 (en) 2009-08-06
ATE363892T1 (en) 2007-06-15
CZ20013185A3 (en) 2002-01-16
TR200102567T2 (en) 2002-01-21
US6528096B1 (en) 2003-03-04
DE69936268D1 (en) 2007-07-19
PL354841A1 (en) 2004-02-23
CY1106817T1 (en) 2012-05-23
AU3409399A (en) 2000-09-28
HUP0200185A2 (en) 2002-06-29
DE69936268T2 (en) 2008-02-14
CZ298489B6 (en) 2007-10-17
PT1158958E (en) 2007-08-13
US20030133880A1 (en) 2003-07-17
HUP0200185A3 (en) 2006-07-28
PL196951B1 (en) 2008-02-29
SK12482001A3 (en) 2002-01-07
DK1158958T3 (en) 2007-10-08
BR9917246A (en) 2002-03-26

Similar Documents

Publication Publication Date Title
US6528096B1 (en) Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation
US9566239B2 (en) Pharmaceutical formulations for dry powder inhalers
EP2272508B1 (en) Pharmaceutical formulations for dry powder inhalers
CA2211874C (en) Carrier particles for use in dry powder inhalers
EP1729728B1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
KR101052693B1 (en) Method for preparing a composition for inhaling dry powder

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION